Warning: include(wp-content/ss): Failed to open stream: No such file or directory in /home/u494663518/domains/reglytiics.com/public_html/wp-content/db.php on line 2

Warning: include(): Failed opening 'wp-content/ss' for inclusion (include_path='.:/opt/alt/php83/usr/share/pear:/opt/alt/php83/usr/share/php:/usr/share/pear:/usr/share/php') in /home/u494663518/domains/reglytiics.com/public_html/wp-content/db.php on line 2
https://reglytiics.com/calendar/2026-01-17T20:58:06+05:30https://reglytiics.com/s%f0%9d%98%81%f0%9d%97%bf%f0%9d%97%b2%f0%9d%97%bb%f0%9d%97%b4%f0%9d%98%81%f0%9d%97%b5%f0%9d%97%b2%f0%9d%97%bb%f0%9d%97%b6%f0%9d%97%bb%f0%9d%97%b4-%f0%9d%97%97%f0%9d%97%ae%f0%9d%98%81%f0%9d%97%ae/2026-02-05T19:38:15+05:30https://reglytiics.com/ema-recommends-approval-of-new-sanofi-medicine-for-chronic-graft-versus-host-disease/2026-02-05T22:54:55+05:30https://reglytiics.com/ema-type-ii-variation-checklist-industry-impact/2026-02-05T12:30:56+05:30https://reglytiics.com/ema-draft-reflection-paper-on-qualification-of-non-mutagenic-impurities-industry-impact/2026-02-05T12:26:35+05:30https://reglytiics.com/ema-reflection-paper-on-non-mutagenic-impurities-industry-impact/2026-02-05T12:26:09+05:30https://reglytiics.com/guidance-on-clinical-decision-support-cds-software-industry-impact/2026-02-05T12:25:31+05:30https://reglytiics.com/fda-launches-precheck-pilot-program/2026-02-05T22:53:03+05:30https://reglytiics.com/chmp-positive-opinion-for-zynyz-retifanlimab/2026-02-06T23:24:01+05:30https://reglytiics.com/chmp-positive-opinion-for-imfinzi-durvalumab/2026-02-04T21:20:47+05:30https://reglytiics.com/chmp-positive-opinion-for-efmody-hydrocortisone/2026-02-05T22:55:04+05:30https://reglytiics.com/ema-pipeline-watch-shaping-the-future-of-medicines-february-2026/2026-02-05T19:17:27+05:30https://reglytiics.com/ema-updates-data-protection-framework-for-eudravigilance/2026-02-05T22:55:12+05:30https://reglytiics.com/india-proposes-new-framework-for-post-approval-changes/2026-02-05T22:52:21+05:30https://reglytiics.com/india-proposes-amendment-to-ndct-rules-on-ethics-committee-registration/2026-02-05T23:05:46+05:30https://reglytiics.com/fda-signals-enforcement-action-against-non-approved-glp-1-drugs/2026-02-07T09:39:44+05:30https://reglytiics.com/fda-guidance-on-computer-software-assurance-csa/2026-02-07T18:15:06+05:30https://reglytiics.com/fda-updates-safety-labeling-for-capecitabine-on-dpd-deficiency-risk/2026-02-07T18:48:12+05:30https://reglytiics.com/fda-issues-emergency-use-authorization-to-address-new-world-screwworm-in-cattle/2026-02-07T21:41:20+05:30https://reglytiics.com/registration-guide-for-upd-ui-and-api-users/2026-02-08T09:39:41+05:30https://reglytiics.com/ema-weekly-update-02-feb-2026-to-08-feb-2026/2026-02-08T10:16:52+05:30https://reglytiics.com/ema-concept-paper-on-revision-of-eu-gmp-annex-15-qualification-validation/2026-02-09T20:28:48+05:30https://reglytiics.com/aemps-ema-chmp-bulletin-january-2026-key-regulatory-highlights/2026-02-10T20:19:32+05:30https://reglytiics.com/ema-prac-safety-signals-update-january-2026/2026-02-10T21:29:42+05:30https://reglytiics.com/fda-draft-guidance-on-certification-process-for-designated-medical-gases-february-2026/2026-02-11T19:59:34+05:30https://reglytiics.com/ema-prac-meeting-minutes-24-27-november-2025/2026-02-12T21:35:58+05:30https://reglytiics.com/ema-guidance-on-preparing-the-precise-scope-section-in-variation-applications/2026-02-12T21:43:37+05:30https://reglytiics.com/ema-concept-paper-on-new-guideline-for-clinical-investigation-in-myasthenia-gravis/2026-02-22T13:36:37+05:30https://reglytiics.com/ema-pharmacovigilance-recommendations-for-centrally-authorised-veterinary-medicines-2026/2026-02-22T13:34:52+05:30https://reglytiics.com/ema-revises-guideline-on-risk-management-requirements-for-elemental-impurities-in-veterinary-medicinal-products-revision-3/2026-02-22T13:41:11+05:30https://reglytiics.com/ema-releases-draft-guideline-on-quality-aspects-of-mrna-vaccines-for-veterinary-use/2026-02-22T13:53:14+05:30https://reglytiics.com/ema-reference-documents-for-electronic-reporting-to-eudravigilance/2026-02-25T08:47:29+05:30https://reglytiics.com/ema-recommends-new-single-dose-oral-treatment-a-major-step-forward-in-global-health/2026-03-01T11:07:42+05:30https://reglytiics.com/meeting-highlights-from-the-committee-for-medicinal-products-for-human-use-chmp-23-26-february-2026/2026-03-01T11:34:00+05:30https://reglytiics.com/ema-concept-paper-on-microbiome-based-medicinal-products-regulatory-direction-for-non-clinical-development/2026-03-03T22:33:13+05:30https://reglytiics.com/hsa-updates-sg-hsa-ectd-specification-for-module-1-and-regional-information-v1-1/2026-03-05T22:52:05+05:30https://reglytiics.com/ema-releases-draft-guidance-on-conducting-clinical-trials-during-public-health-emergencies/2026-03-07T13:44:30+05:30https://reglytiics.com/fda-draft-guidance-on-responding-to-form-483-observations-after-drug-cgmp-inspections/2026-03-08T21:20:32+05:30https://reglytiics.com/new-and-revised-draft-qas-on-biosimilar-development-andthe-bpci-act-revision-4-guidance-for-industry/2026-03-11T22:30:31+05:30https://reglytiics.com/safety-update-ema-recommends-product-warning-for-chikungunya-vaccine-ixchiq/2026-03-14T21:39:41+05:30https://reglytiics.com/ema-releases-new-ctis-sponsor-faqs-key-clarifications-for-clinical-trial-sponsors/2026-03-27T09:42:45+05:30https://reglytiics.com/ema-post-authorisation-procedural-advice-what-marketing-authorisation-holders-need-to-know/2026-03-29T10:29:12+05:30https://reglytiics.com/fda-issues-guidance-on-voluntary-patient-preference-information-across-the-medical-device-lifecycle/2026-04-01T09:08:44+05:30https://reglytiics.com/ema-revises-guideline-for-clinical-investigation-of-scig-imig-products/2026-04-04T12:17:19+05:30https://reglytiics.com/advice-on-orphan-status-and-clinical-advice-advice-on-the-clinical-development-strategy-or-clinical-data-required-for-the-clinical-evaluation/2026-04-09T23:28:54+05:30https://reglytiics.com/draft-amendment-to-medical-devices-rules-2017-released-for-public-consultation/2026-04-11T13:24:53+05:30